With global cases of AMD, DME, and glaucoma rapidly increasing, ophthalmic drug R&D is accelerating to meet urgent unmet needs. However, poor treatment adherence, invasive procedures, and adverse side effects continue to limit therapeutic success, highlighting the critical need for optimized delivery approaches.

Recent developments, including Genentech’s Susvimo label expansion, advances in sustained-release and suprachoroidal delivery systems, and Regeneron’s acquisition of Oxular, demonstrate a growing industry focus on improving durability and reducing invasiveness.

That’s why 80+ industry leaders will gather at the 4th Ophthalmic Drug Delivery Summit this January to explore long-acting intravitreal and subretinal innovations, emerging suprachoroidal techniques, novel formulation strategies, drug-device integration, and evolving regulatory expectations.

Join experts across preclinical and clinical R&D, formulation, pharmacology, devices, and combination products for three days of focused discussions driving the future of safe, effective, and durable ophthalmic therapies.

Download the full event guide to find out all the topics to be discussed and the full expert speaker faculty: https://ter.li/vz7y60